- Health
- SEE MORE
- classical
- general
- talk
- News
- Family
- Bürgerfunk
- pop
- Islam
- soul
- jazz
- Comedy
- humor
- wissenschaft
- opera
- baroque
- gesellschaft
- theater
- Local
- alternative
- electro
- rock
- rap
- lifestyle
- Music
- como
- RNE
- ballads
- greek
- Buddhism
- deportes
- christian
- Technology
- piano
- djs
- Dance
- dutch
- flamenco
- social
- hope
- christian rock
- academia
- afrique
- Business
- musique
- ελληνική-μουσική
- religion
- World radio
- Zarzuela
- travel
- World
- NFL
- media
- Art
- public
- Sports
- Gospel
- st.
- baptist
- Leisure
- Kids & Family
- musical
- club
- Culture
- Health & Fitness
- True Crime
- Fiction
- children
- Society & Culture
- TV & Film
- gold
- kunst
- música
- gay
- Natural
- a
- francais
- bach
- economics
- kultur
- evangelical
- tech
- Opinion
- Government
- gaming
- College
- technik
- History
- Jesus
- radio
- movies
- services
- Church
- podcast
- Education
- international
- Transportation
- Other
- kids
- podcasts
- philadelphia
- Noticias
- love
- sport
- Salud
- film
- and
- 4chan
- Disco
- Stories
- fashion
- Arts
- interviews
- hardstyle
- entertainment
- humour
- medieval
- literature
- alma
- Cultura
- video
- TV
- Science
- en
Advances in Reducing Respiratory Events From Cystic Fibrosis with Greg Duncan Celtaxsys
Greg Duncan, CEO, Celtaxsys tells us about the work the company is doing to help reduce pulmonary exacerbations in patients with cystic fibrosis. Cystic fibrosis is a rare genetic life-threatening disease that affects over 70,000 people worldwide. Pulmonary exacerbations are sudden, severe respiratory events that ultimately lead to lung function decline. Celtaxsys\u2019 lead candidate, once-daily anti-inflammatory acebilustat, which the company is currently progressing to Phase 3 development, has the potential to prevent lung function decline by reducing the frequency of pulmonary exacerbations.
#cysticfibrosis #CFresearch #RareDisease #CFAware #acebilustat
Celtaxsys.com
\xa0